Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial

Trial Profile

Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors BIAL - Portela C S.A.
  • Most Recent Events

    • 27 Apr 2018 Results (n=418) of a pooled analysis assessing predictors of response to placebo from 093-301, -302, and -304 studies, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 27 Apr 2018 Results of analysis investigating MCID in seizure frequency using patient data pooled from NCT01422720, NCT00957047 and NCT00988429 trials presented at the 70th Annual Meeting of the American Academy of Neurology
    • 27 Apr 2018 Results of analysis evaluating the impact of potential missing seizure diary data on primary efficacy outcomes, using patient data from NCT00957047 and NCT00988429 trials presented at the 70th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top